Literature DB >> 12891909

[The prostate cancer in the community of Madrid in 2000 I.- Incidence].

F Herranz Amo1, F Arias Funez, M Arrizabalaga Moreno, F J Calahorra Fernández, J Carballido Rodríguez, R Diz Rodríguez, J A Herrero Payo, C Llorente Abarca, J C Martín Martínez, L Martínez-Piñeiro Lorenzo, R Mínguez Martínez, J Moreno Sierra, A Rodríguez Antolín, J C Tamayo Ruiz, J Turo Antona.   

Abstract

OBJECTIVE: To know the incidence in the year 2000 of prostate cancer in the Autonomous Community of Madrid and its breakdown by Health Areas. MATERIAL AND
METHOD: Study of histologically confirmed prostate cancer case reports and retrospective data acquisition for 2000 in the Autonomous Community of Madrid, both from Public and Private Health Care hospitals.
RESULTS: Gross incidence of prostate cancer in the Autonomous Community of Madrid was 100.4 cases per 100,000 males. The incidence adjusted for the Spanish, European and Worldwide population was 120.1, 103.5 and 68.6 cases per 100,000 males, respectively. Mean age at diagnosis was 70 +/- 7.8 (40-94) years, median of 70 years. The age group with higher incidence was 70 to 79 years.
CONCLUSIONS: The incidence of prostate cancer in the Autonomous Community of Madrid is lower than that in the US but higher than in most countries or regions in the EU. The different way of using PSA testing in the Health Areas of the Autonomous Community may explain the differences seen in terms of incidence by Area.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12891909     DOI: 10.1016/s0210-4806(03)72933-7

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  1 in total

1.  Androgen receptor coregulators NOCR1, TIF2, and ARA70 may account for the hydroxyflutamide insensitivity of prostate cancer cells.

Authors:  Y Wang; J-Q Li; C Shao; C-H Shi; F Liu; Z-Y Yang; J-X Qiu; Y-M Li; Q Fu; W Zhang; W Xue; Y-H Lei; J-Y Gao; J-Y Wang; X-P Gao; J-L Yuan; T-Y Bao; Y-T Zhang
Journal:  Ir J Med Sci       Date:  2011-07-05       Impact factor: 1.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.